Large-scale testing (Phase 3)Study completedNCT01350804
What this trial is testing
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
Who this might be right for
Rheumatoid Arthritis
Novartis Pharmaceuticals 551